MPNs

During a live virtual event, Ruben Mesa, MD, discussed the clinical trials and challenges of using ruxolitinib for patients with myelofibrosis.

Changes like bone marrow fibrosis improvement and variant allele frequency reduction were seen with navitoclax plus ruxolitinib in patients with previously treated myelofibrosis in the REFINE study.

Srdan Verstovsek, MD, PhD, discusses the tolerability of pacritinib for patients with myelofibrosis.

During a live virtual event, Ruben Mesa, MD, discussed the use and sequencing of JAK inhibitors and stem cell transplant for patients with myelofibrosis.

In an interview with Targeted Oncology, Ghaith Abu-Zeinah, discussed the factors contributing to overall survival in patients with polycythemia vera and what is expected of future research.

Following PERSIST-1 and PERSIST-2 and a recent FDA approval, pacritinib is being investigated in a phase 3 study versus physician's choice of standard therapy in patients with myelofibrosis.

Carole Miller, MD, discusses the REVEAL study which enrolled patients with polycythemia vera at both academic and community practices.

Ghaith Abu-Zeinah, MD, discusses the unmet needs investigational drugs could address for patients with polycythemia vera.

John Mascarenhas, MD, summarizes the treatment landscape for myelofibrosis, which now includes of pacritinib.

Srdan Verstovsek, MD, discussed the ways in which ropeginterferon and rusfertide can reduce thromboembolic events in polycythemia vera.

In the REFINE trial treatment with navitoclax to ruxolitinib in patients with myelofibrosis, spleen reduction has been observed.

The NCCN guidelines for myeloproliferative neoplasms now include ropeginterferon alfa-2b, which was recently granted FDA approval for the treatment of polycythemia vera.

John Mascarenhas, MD, provides advice to oncologists on the use of pacritinib to treatment patients with myelofibrosis and severe thrombocytopenia.

John Mascarenhas, MD, discusses the mechanism of action of pacritinib and how it differs from ruxolitinib and fedratinib.

In an interview with Targeted Oncology, John Mascarenhas, MD, discussed the introduction of pacritinib to the treatment landscape for myelofibrosis and severe thrombocytopenia, and the research supporting the recent FDA approval.

The FDA has approved pacritinib for the treatment of patients with myelofibrosis and severe thrombocytopenia.

Thromboembolic events and risk of progression continue to affect patients with polycythemia vera, but 2 recent advances may affect the natural course of the disease.

The future of myelofibrosis may include several JAK inhibitor treatment niches as well as combination regimens with JAK inhibition in both the upfront and second-line setting and more, according to John Mascarenhas, MD.

Richard Silver, MD, discusses the Interferon Initiative organized by the Myeloproliferative Neoplasm Research Foundation.

Srdan Verstovsek, MD, discussed maintaining hematocrit levels in patients with polycythemia vera as well as research on the use of rusfertide.

During a Targeted Oncology case-based roundtable event, Ruben Mesa, MD, discussed risk assessment and management of myeloproliferative neoplasms.

Srdan Verstovsek, MD, PhD, discusses the main reasons for his study on the use of rusfertide in patients with polycythemia vera.

The MOMENTUM trial of momelotinib showed efficacy in treating symptoms of myelofibrosis, according to a press release.

In an interview with Targeted Oncology, Yelena Ginzburg, MD, discussed the research and use of rusfertide in patients with polycythemia vera.

Results from the ongoing phase 3 MOMENTUM clinical trial may be available by the end of Janaury 2022.